Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Wave Life Sciences (WVE) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Wave Life Sciences (WVE) over the last 11 years, with Q2 2025 value amounting to 579.68%.

  • Wave Life Sciences' EBITDA Margin fell 4120700.0% to 579.68% in Q2 2025 from the same period last year, while for Sep 2025 it was 682.43%, marking a year-over-year decrease of 4499200.0%. This contributed to the annual value of 89.7% for FY2024, which is 388600.0% down from last year.
  • According to the latest figures from Q2 2025, Wave Life Sciences' EBITDA Margin is 579.68%, which was down 4120700.0% from 510.3% recorded in Q1 2025.
  • Wave Life Sciences' EBITDA Margin's 5-year high stood at 14.67% during Q3 2023, with a 5-year trough of 13712.28% in Q3 2022.
  • For the 5-year period, Wave Life Sciences' EBITDA Margin averaged around 2379.74%, with its median value being 510.3% (2025).
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by -136951500bps in 2022, then skyrocketed by 137269500bps in 2023.
  • Quarter analysis of 5 years shows Wave Life Sciences' EBITDA Margin stood at 1975.18% in 2021, then tumbled by -78bps to 3520.18% in 2022, then soared by 98bps to 55.75% in 2023, then crashed by -201bps to 167.6% in 2024, then tumbled by -246bps to 579.68% in 2025.
  • Its EBITDA Margin stands at 579.68% for Q2 2025, versus 510.3% for Q1 2025 and 167.6% for Q2 2024.